No Data
Zhejiang Jingxin Pharmaceutical (002020.SZ): There are currently no plans to enter the Ophthalmology field.
Gelonghui December 26丨 Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company has no current plans to enter the Ophthalmology field.
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Sheds 4.2% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Zhejiang Jingxin Pharmaceutical (002020.SZ): Didanosine is a globally unique exclusive variety.
On December 18, Gelonghui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on an investor interaction platform that the company's Didasini is a globally innovative exclusive variety, and multiple patents are currently under protection.
Zhejiang Jingxin Pharmaceutical (002020.SZ): The company's diadizine is a globally innovative exclusive variety, with multiple patents still under protection.
Glory Financial, December 18 – Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company's dadarizine is a globally pioneering exclusive variety, and currently multiple patents are within the protection period.
Zhejiang jingxin pharmaceutical (002020.SZ): The enteric-coated capsules for rehabilitation are currently nearing the end of Phase II clinical trials.
Glemanet December 3rd | zhejiang jingxin pharmaceutical (002020.SZ) stated on the investor interaction platform on December 3rd that the recovery new enteroic capsule is currently in the late stage of phase II clinical trials, and the company will proceed with the phase III clinical trials of this variety as soon as possible after the completion of phase II according to plan.
Are Robust Financials Driving The Recent Rally In Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) Stock?
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Jumps 5.8% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
